IntegraGen SA: Advancing Biomarker Research in Healthcare

Integragen SA, a France-based company operating in the healthcare sector, has been making significant strides in the field of biotechnology. The company specializes in researching and developing biomarkers for diagnostic tools across various medical fields, including autism, oncology, diabetes, and obesity. As of the close of trading on June 30, 2025, IntegraGen’s stock was priced at 0.49 EUR on the NYSE Euronext Paris, reflecting a notable fluctuation over the past year with a 52-week high of 0.86 EUR on January 8, 2025, and a low of 0.434 EUR on November 26, 2024.

IntegraGen’s innovative approach involves using an evaluation model that targets several autism-related genes. This model employs a combination of common polymorphisms, known as Single-Nucleotide Polymorphisms (SNPs), to enhance diagnostic accuracy. Additionally, the company is at the forefront of developing molecular biomarker validation programs. These programs focus on Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers, which are crucial for advancing cancer treatment strategies.

Beyond biomarker development, IntegraGen offers a range of genomics services to practitioners and researchers. These services include DNA extraction, marker selection and tagging, and bioinformatical analysis of sequence data. The company’s expertise spans various fields such as pharmacogenetics, cytogenetics, epigenetics, mutation searches, and SNP discovery. This comprehensive suite of services positions IntegraGen as a key player in the genomics landscape.

As of December 31, 2011, IntegraGen expanded its operations through its wholly owned subsidiary, IntegraGen Inc., further solidifying its presence in the global biotechnology market. The company’s commitment to advancing healthcare through innovative research and development continues to drive its growth and influence in the sector.

In summary, IntegraGen SA remains a pivotal entity in the healthcare and biotechnology industries, with its focus on biomarker research and genomics services contributing to significant advancements in medical diagnostics and treatment.